Clinical Trials Directory

Trials / Terminated

TerminatedNCT02183727

L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction

L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction: A Prospective, Randomized Controlled Trial

Status
Terminated
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Soft Tissue Regeneration, Inc. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare safety and efficacy outcomes of the L-C Ligament versus Hamstring Autograft for treatment of acute rupture of the ACL.

Conditions

Interventions

TypeNameDescription
DEVICEL-C LigamentThe L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
PROCEDUREHamstring AutograftThe gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.

Timeline

Start date
2015-09-01
Primary completion
2020-06-01
Completion
2020-07-01
First posted
2014-07-08
Last updated
2021-11-22

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02183727. Inclusion in this directory is not an endorsement.